Inadequate Warnings Expand Onglyza MDL

Inadequate Warnings Expand Onglyza MDL

Introduction

A growing number of Onglyza lawsuits are fast becoming a part of MDL No. 2809 established in February for coordinated pretrial proceedings. AstraZeneca and Bristol Myers Squibb are the defendants named in this litigation. Cases have been coordinated in the U.S. District Court for the Eastern District of Kentucky under District Judge Karen K. Caldwell.

Recently, a lawsuit was filed in the U.S. District Court for the Eastern District of Kentucky by a plaintiff, who claims that the use of Onglyza and Kombiglyze XR led to the development of his heart failure and other related injuries, which could have been avoided if the drug makers had provided adequate warnings. His claim also details how the defendants continued to market Onglyza and Kombiglyze XR as safe and effective, in spite of being well aware of the heart failure risks.